Competitor News, Product Updates

Verana Health to Enable Cloud-based Access to its Curated, De-identified Real-World Data Through AWS Data Exchange

SAN FRANCISCO, Nov. 30, 2022 /PRNewswire/ — Verana Health®—a digital health company elevating quality in real-world data (RWD)—today announced that its curated, de-identified real-world data (RWD) and Qdata™ modules will soon be available to license in AWS Data Exchange, an Amazon Web Services (AWS) cloud-native service that makes it easy for AWS customers to find, subscribe…

Collaborations, Competitor News, Product Updates

Lumanity Announces Strategic Partnership with HealthVerity to Provide Streamlined Access to Real-World Data, World-Class Analytics, and Value Demonstration Expertise

Lumanity Announces Strategic Partnership with HealthVerity to Provide Streamlined Access to Real–World Data, World-Class Analytics, and Value Demonstration Expertise Lumanity’s deep data analytics, value demonstration, and therapeutic area expertise alongside HealthVerity’s patient identity resolution technology and leading ecosystem of interoperable real-world data enables evidence generation across the pharma lifecycle New York, November 28, 2022 – Lumanity and HealthVerity today announced…

Government/Regulatory, Industry News

Collaboration Makes The (Real) World Go Round: Global Efforts Strive To Anchor RWE With Real-World Data Standards And Practices

It is striking how collaborative the real-world evidence (RWE) ecosystem is: a distributed community with multiple nodes of authority working toward a coherent, transparent approach to real-world data and evidence generation that can enhance a global industry. “Big data has changed everything,” US FDA Office of Medical Policy associate director…

Collaborations, Competitor News, Oncology, Pharma

Aetion Leads Cross Industry Initiative to Understand Strengths and Limitations of Regulatory Use of Real-World Evidence

The Aetion CARE Initiative aims to become the standard bearer for best practices and efficiencies in RWE development and decision making NEW YORK, Nov. 29, 2022 /PRNewswire/ — Aetion, the global leader in real-world evidence (RWE) technology and analytics, today announced the launch of the Coalition for the Advancement of RWE through Randomized…

Competitor News, Product Updates, Synthetic Data

ConcertAI’s TeraRecon Expands AI, Partner, and Advanced Imaging Solutions at #RSNA22, Helping Clinicians Improve Efficiency and Care with Next Generation Eureka Clinical AI Platform

CAMBRIDGE, Mass., Nov. 28, 2022 /PRNewswire/ — ConcertAI’s TeraRecon, a leader in advanced visualization and artificial intelligence (AI) for medical imaging, recently unveiled first-in-category capabilities in advanced visualization, AI, and an AI solutions partner ecosystem to better meet clinician requirements in complex clinical workflows providing key augmentations enabling better outcomes for their patients….

Academic, Collaborations, Europe, Government/Regulatory, Industry News, International

Significant EU funding for implementing value-based cancer care at European cancer hospitals

November 25, 2022 The EU has awarded 7 MEUR to HUS Helsinki University Hospital led Consortium, which aims to unlock the full potential of real-world data collected in European cancer hospitals. This in turn will support the implementation of safer, more efficient, and personalized novel cancer therapies. “To implement value-based…

Collaborations, Competitor News, Europe, Government/Regulatory, International

BC Platforms Partners with EU Funded, AI-Driven, Cancer Data Initiative

ZURICH, Nov. 24, 2022 /PRNewswire/ — BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced that it has been chosen as key partner in a European Commission (EC) project. Under the EC’s Horizon Europe program*, Helsinki University Hospital (HUS), has been awarded a contract to lead a EURO 7 million (approx. USD…

Competitor News, Events, Marketing


The Future of Real-World Evidence: Pharma’s Next Moves, Upcoming Webinar Hosted by Xtalks

TORONTO (PRWEB) NOVEMBER 23, 2022 Throughout the pharma industry, real-world evidence (RWE) is leveraged across organizations for key decision-making within a therapy’s life cycle — from R&D to new US Food and Drug Administration (FDA) drug submissions to commercial strategy operations. Companies are choosing to invest heavily to build in-house capabilities…